Novel and Emerging Therapies for Food Allergy | FDA Skip to main content Skip to

Competitive Generic Therapies | FDA Skip to main content Skip to FDA Search Skip to

Competitive Generic Therapies | FDA Skip to main content Skip to FDA Search Skip to

FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease | FDA Skip to main content

Identification of Targets for Development of Vaccines and Biological Therapies Against Gastrointestinal Pathogens | FDA

Gene Therapies Advisory Committee Charter of the Cellular, Tissue and Gene Therapies Advisory Committee Roster of

the use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic

Frequently Asked Questions: Breakthrough Therapies | FDA Skip to main content Skip to FDA Search Skip to

Important Patient and Consumer Information About Regenerative Medicine Therapies | FDA Skip to main content Skip to

FDA approves two therapies to treat IBS-D Skip to main page content Skip to

Older Therapies Aren’t Necessarily Better for Thyroid Hormone Replacement | FDA Skip to main

Older Therapies Aren’t Necessarily Better for Thyroid Hormone Replacement | FDA Skip to main

Products Resources Related to Regenerative Medicine Therapies Share Post Linkedin Email Print Regenerative medicine therapies (RMTs) are defined in

Resources Related to Regenerative Medicine Therapies | FDA Skip to main content Skip to FDA Search

Novel and Emerging Therapies for Food Allergy | FDA Skip to main content Skip to

PDA 02 2021 Cryopreservation of Cells for Use in Cell Therapies, Gene Therapies, and

Gene Therapies Advisory Committee Charter of the Cellular, Tissue and Gene Therapies Advisory Committee Roster of

Gene Therapies Advisory Committee Charter of the Cellular, Tissue and Gene Therapies Advisory Committee Roster of

Be Aware of Potentially Dangerous Products and Therapies that Claim to Treat Autism | FDA Skip

Gene Therapies Advisory Committee Charter of the Cellular, Tissue and Gene Therapies Advisory Committee Roster of

Gene Therapies Advisory Committee Charter of the Cellular, Tissue and Gene Therapies Advisory Committee Roster of

Expedited Programs for Regenerative Medicine Therapies for Serious Conditions | FDA Skip to main content Skip

Important Patient and Consumer Information About Regenerative Medicine Therapies | FDA Skip to main content Skip to

Voluntary Consensus Standards Recognition Program for Regenerative Medicine Therapies | FDA Skip to main content Skip to

Tissue Agnostic Therapies: Regulatory Considerations for Orphan Drug Designation; Public Workshop - 05/09/2018 | FDA Skip to

Evaluation of Devices Used with Regenerative Medicine Advanced Therapies | FDA Skip to main content Skip to

Identification of Targets for Development of Vaccines and Biological Therapies Against Gastrointestinal Pathogens | FDA

FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease | FDA Skip to main content

Research (Biologics) Biologics Research Projects Tissue & Advanced Therapies Research Biologics Research Projects Tissue & Advanced Therapies Research Share Post Linkedin

Regulatory Process for the Office of Tissues and Advanced Therapies | FDA Skip to

FDA Takes Steps to Advance the Development of Novel Therapies for Stimulant Use

Gene Therapies Advisory Committee Charter of the Cellular, Tissue and Gene Therapies Advisory Committee Roster of

FDA announces Project Facilitate to assist physicians seeking access to unapproved therapies for patients with

FDA Public Workshop on Tissue Agnostic Therapies: Regulatory Considerations for Orphan Drug Designation - 05/09/2018 | FDA Skip to

Tissue & Advanced Therapies Research | FDA Skip to main content Skip to FDA Search Skip to

Regulatory Process for the Office of Tissues and Advanced Therapies | FDA Skip to

Accelerating Access to Critical Therapies for ALS Act – ACT for ALS | FDA Skip to

Be Aware of Potentially Dangerous Products and Therapies that Claim to Treat Autism | FDA Skip

Advancing Rare Disease Therapies Through an FDA Rare Disease Innovation Hub - 10/16/2024 | FDA Skip to main

zamikeracel) Abeona Therapeutics, Inc. ZYNTEGLO (betibeglogene autotemcel) bluebird bio, Inc. ZOLGENSMA (onasemnogene abeparvovec-xioi) Novartis Gene Therapies, Inc. Content current as

Cell Therapies and Tissue-Based Products: A Public Workshop on Generating Scientific Evidence to

SmartCore Technology: Using AI and Patient Tissue to Identify Potential Cancer Therapies for Ultra-rare

Workshop on Integration Site Analysis During Long Term Follow-Up for Gene Therapies with Integrating Viral Vectors - 11/14

FDA Launches Framework for Accelerating Development of Individualized Therapies for Ultra-Rare Diseases | FDA Skip

FDA Launches Framework for Accelerating Development of Individualized Therapies for Ultra-Rare Diseases | FDA Skip

of products including purified and recombinant proteins for hematology, antivenins, gene therapies, cell therapies, therapeutic tissue

Cellular, Tissue, and Gene Therapies Advisory Committee March 10, 2022 Meeting Announcement - 03/10/2022 | FDA Skip to

of products including purified and recombinant proteins for hematology, antivenins, gene therapies, cell therapies, therapeutic tissue

Cellular, Tissue, and Gene Therapies Advisory Committee October 31, 2023 Meeting Announcement - 10/31/2023 | FDA Skip to

Cellular, Tissue, and Gene Therapies Advisory Committee September 27, 2023 Meeting Announcement - 09/27/2023 | FDA Skip to

for adult patients with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic

Focuses on Novel Drug Development Tools to Help Speed Creation of New Therapies | FDA Skip to

Cellular, Tissue, and Gene Therapies Advisory Committee June 29-30, 2022 Meeting Announcement - 06/29/2022 | FDA Skip to

Cellular, Tissue, and Gene Therapies Advisory Committee June 9-10, 2022 Meeting Announcement - 06/09/2022 | FDA Skip to

Creating a Public-Private Partnership to Support Development of Anti-Cancer Therapies for Ultra

FDA Launches Framework for Accelerating Development of Individualized Therapies for Ultra-Rare Diseases | FDA Skip

Cellular, Tissue, and Gene Therapies Advisory Committee May 12, 2023 Meeting Announcement - 05/12/2023 | FDA Skip to

Cellular, Tissue, and Gene Therapies Advisory Committee May 12, 2023 Meeting Announcement - 05/12/2023 | FDA Skip to

tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, except for

approved the first gene therapy in 2017 and 19 gene therapies as of June

Investigating Deaths Due to Acute Liver Failure Following Treatment with Sarepta’s AAVrh74 Gene Therapies | FDA Skip to

of novel product development. Regulatory Information Flexible Requirements for Cell and Gene Therapies to Advance

important stakeholders and FDA staff to discuss foundational information about regenerative medicine therapies, such as gene and

Other Biologics Allergenic Products Advisory Committee Blood Products Advisory Committee Cellular, Tissue, and Gene Therapies Advisory Committee Transmissible Spongiform

such as some probiotics); and the rapidly growing group of cell therapies, gene therapies, and

risks associated with these products. Read these Consumer Updates to learn more. Hormone Replacement Therapies Can Help Women with

Products Tobacco Products Vaccines, Blood & Biologics Artículos para el consumidor en español Image Hormone Replacement Therapies Can Help Women with

Products Tobacco Products Vaccines, Blood & Biologics Artículos para el consumidor en español Image Hormone Replacement Therapies Can Help Women with

priorities: Public health crisis response - Products addressing urgent/emerging threats or significant population impact.  Innovative breakthrough therapies - Transformative treatments with novel

and Partnerships   Brenton McCright, Ph.D. Office of Tissues and Advanced Therapies Division of Cellular

the-counter medicines Biologics such as blood components, blood/plasma derivatives and gene therapies. Medical devices such as

of a new drug is expedited. Accelerated Approval can be applied to promising therapies that treat a

hospital or outpatient infusion centers. Biologics such as blood components, blood/plasma derivatives, blood transfusions, gene therapies, and human

Process for the Office of Cellular, Tissue and Gene Therapies Good Tissue Practice &

assessing the risks and benefits to patients of unapproved therapies. The agency

of products under 21 CFR part 1271 Development and regulation of cellular therapies, gene therapies, and

877-CTP-1373 (1-877-287-1373) (9 a.m. - 4 p.m. Eastern) Questions About Nicotine Replacement Therapies and Smoking

Revised Covid-19 vaccine framework Launched CEO listening tour with industry executives Unleashing cutting-edge gene therapies Approved first Alzheimer's

products for rare diseases and conditions Accelerating Access to Critical Therapies for ALS

for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies; Guidance for Industry

better support innovation and patient access to safe and effective therapies. Please use the

Revised Covid-19 vaccine framework Launched CEO listening tour with industry executives Unleashing cutting-edge gene therapies Approved first Alzheimer's

Revised Covid-19 vaccine framework Launched CEO listening tour with industry executives Unleashing cutting-edge gene therapies Approved first Alzheimer's

Collaborations and Partnerships Ronit Mazor, PhD Office of Tissues and Advanced Therapies Division of Cellular